NYSE · TEVA
Teva Pharmaceutical Industries Limited
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
Loading market information…
NASDAQ · VTRS · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Viatris Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Viatris Inc.’s forward annual dividend is $0.48 per share, paid quarterly. The forward yield is 2.5% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Viatris Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.64. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Viatris Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| May 8, 2025 |
| $0.50+1.65% vs estimate |
| $3.25B+0.59% vs estimate |
| Q4 2024 | Feb 27, 2025 | $0.54-11.48% vs estimate | $3.53B-2.0% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.75+10.78% vs estimate | $3.74B+0.61% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
$8.57-$1.43 (-14.3%)
Haleon plc’s quoted price sits in the lower half of its reported 52-week range, 24.02% below the high.
$14.11-$0.04 (-0.28%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 9.96% below the high.
$45.37+$0.12 (+0.27%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
$21.35+$0.21 (+0.99%)
Amneal Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.52% below the high.
₹1,926.20-₹4.30 (-0.22%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
$13.81+$0.03 (+0.22%)
Organon & Co.’s quoted price sits in the upper half of its reported 52-week range, 0.14% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
